Biotech industry publication EndPoints cited William Blair investment banking’s “Quarterly Rx” report for its story on the current state of life sciences sector IPOs.
Among the factors impacting IPOs for life sciences companies, the report cited by EndPoints notes, is an increase in the time between the crossover funding round and an IPO, and the increased gap between the series B and series C funding rounds on average.